AMCP Dossier Requirements for Formulary Submission

Every U.S. pharmaceutical company prepares the AMCP Format for Formulary Submissions prior to requesting that a health plan add a new product to its coverage. This document bridges a critical gap by offering P&T committees uniform evidence standards while providing manufacturers with an established structure for their submissions.

The AMCP Format as the Default Dossier Standard

The dossier's audience is the Pharmacy and Therapeutics (P&T) committee, a panel of pharmacists, physicians, nurses, and administrators that reviews clinical evidence, comparative effectiveness, and cost for each product under formulary consideration. That committee structure appears across health plans, accountable care organizations, pharmacy benefit managers, and integrated delivery networks.

Nothing requires a manufacturer to use the AMCP Format. It carries no regulatory force. AMCP describes it as guidance, and manufacturers retain final discretion over how they communicate their evidence. Yet in practice, it has become the default request from P&T committees anyway, which makes it a standard enforced by convention rather than law. No such body exists in the U.S. The Format's authority comes entirely from the fact that the industry adopted it and kept using it. AMCP has already opened and closed a public comment period for a Version 6.0 update, though a publication date for that next edition has not been confirmed.

How the Format is structured across its major sections

The dossier comprises four substantive sections plus an appendix, each fulfilling a specific evidentiary role that reviewers consistently expect to locate in the same position. Section 1 presents product details including the FDA-approved label, how the therapy works, the requested formulary tier, dosing guidance, and any applicable REMS requirements. Section 2 contains the clinical evidence and typically represents the most densely packed portion of the dossier. It covers pivotal controlled trial results for effectiveness and tolerability, subgroup evaluations, direct comparative studies when available, indirect analyses and network meta-analytic methods when unavailable, real-world data drawn from insurance claims, clinical records, patient registries, or self-reported outcomes, as well as an evaluation of illness impact and treatment gaps within the insured population.

Section 3 moves to the economic case. Manufacturers supply three economic pieces: a plan-adaptable budget impact model for local members and costs, cost-effectiveness results stated for each QALY gained or outcome achieved, plus HEOR evidence on treatment-taking behavior, care use, and work output. The appendix gathers complete clinical study documentation, model technical write-ups, relevant literature, and its own Version 5.0 addition addressing information exchange before approval.

None of this is supposed to stay the same after it gets turned in. AMCP designed the Format to evolve continuously, tracking a product through every stage before and after authorization. This dossier serves as a thorough evidence compilation, unlike the brief promotional tool that account managers rely on out in the field. Medical and pharmacy directors are the ones who specifically request this thorough compilation when conducting P&T evaluations. Mixing up the two happens often, and it is a costly mistake.

How Version 5.0's additions reflect payer priorities in 2024

Each subject added in Version 5.0, from real-world evidence and health equity to digital therapeutics alongside pre-approval dialogue and conciseness, addresses a specific obstacle payers encountered with prior dossiers. The most obvious illustration involves real-world data. Although payers informed AMCP of their desire to incorporate RWE into coverage choices, they frequently lacked visibility into what manufacturers possessed and therefore needed to ask for it outright rather than locating it in the anticipated spot. To address this, the updated framework gives RWE a more prominent position within Section 2.

Health equity guidance also makes its Format debut here, offering recommendations on addressing health disparities stemming from social and demographic influences, plus pharmacoequity in general. Digital therapeutics come with their own new expectations as well: companies making prescription DTx products must now address how well their software works with existing systems, HIPAA-compliant protection of data, metrics tracking user engagement, and the usability of devices.

Manufacturers setting submission timelines should pay close attention to the appendix on pre-approval information exchange. The appendix brings AMCP into line with the 2022 Pre-approval Information Exchange Act, and the Format calls for sending these materials to payers in the six-to-twelve-month period before expected product approval. Account for that lead time at the outset of launch planning, because once approval is granted, a newly assembled dossier no longer serves the pre-approval purpose.

Brevity is the last big change, and it grew out of what healthcare decision-makers told AMCP most often: the dossiers had become too long. Under Version 5.0, suggested page limits for Disease Description shrink, urging manufacturers to rely on visual aids and hyperlinks linking within or outside the document rather than duplicating material across sections, though such moves are hardly new. When Version 4.0 arrived in April 2016, it tackled comparative effectiveness research alongside companion diagnostics, medical devices, and biosimilars because formulary debates then centered on those areas.

How manufacturers should build dossiers for payer use

Payers do not go through a dossier from the first page to the last like they would a novel. Reviewers instead pull out the points they need to prepare P&T committee resources and guide formulary decisions, using the dossier as a reference source rather than a file to assess from beginning to end. Petauri-referenced research found that payers, at 83%, treat materials submitted before approval as backup information rather than as their main source. That one figure changes the whole submission job: the dossier is not there to persuade by itself, but to supply internal payer materials that are faster and better informed.

This recasts the notion of "quality" in a submission, since the Format's fondness for concise text, tabular summaries, graphics, and linked material is no mere stylistic whim AMCP adopted on its own. It mirrors the way P&T reviewers really go about extracting information when time is tight. If a reviewer must pull one figure to drop into a committee deck, a submission whose budget impact assumptions sit buried in dense prose undermines itself, however rigorous the underlying analysis.

When manufacturers get this wrong, the consequences go beyond waiting longer for the readout. If a review drops in priority, a manufacturer may lose months of launch-stage formulary access, just as initial placement can steer prescribing behavior for years.

Who hands over the dossier matters here as well. Payers have voiced a preference for clinically or scientifically credentialed people, working in medical affairs, science, or HEOR, rather than sales or account staff, though manufacturers still make that call themselves. The Format also builds in a bidirectional exchange on purpose: a dossier should get a conversation going with the payer rather than end things by leaving one document at the door.

What AMCP's new standards change about real-world evidence

Real-world evidence is where the dossier most sharply exposes the divide between payer demands and payer confidence. Bridging it requires a stronger case than simply adding another stack of observational analyses. It means anticipating and addressing how P&T reviewers are likely to question evidence that was not generated through random assignment.

AMCP's RWE Initiative surfaced this issue in its initial form: payers frequently could not tell which RWE was available for a particular therapy, needed to request it themselves, and had much less practice assessing observational research than they had assessing data from randomized clinical trials. On top of that sits a lasting wariness of studies funded by manufacturers, and a question P&T reviewers bring up more than nearly any other RWE criticism: does the patient population in this study really look like the membership of our own plan?

Interest and use sit far apart. When AMCP's Research Institute polled payers, 80% expressed a desire to draw on RWE when choosing which drugs to cover, yet just a handful said they did so routinely. The distance between what payers say they prefer and what they actually do is nowhere near that small.

AMCP has sought to narrow that gap. Through a years-long RWE program, AMCP Research Institute joined forces with IQVIA, insurers, and drugmakers to craft standards centered on payer needs: a framework describing RWE study designs and outcomes, plus a payer-oriented checklist that companies can adapt when presenting RWE to those making coverage decisions. JMCP carried the standards in its September 2025 issue. That is a real step forward, one that merits recognition as such.

Even so, it does not fix the basic problem. The Format sorts evidence into the appropriate sections, but it does not judge its quality; adequacy is for the reviewing P&T committee to decide. The added RWE checklist functions only as guidance. And the bigger critique still applies: with a voluntary, manufacturer-driven Format, payers still rely on whatever evidence manufacturers decide to choose and show.

IRA Drug Price Negotiation and the Formulary Submission Environment

With the Inflation Reduction Act, Medicare’s negotiation process brings a new stakeholder into how manufacturers frame dossiers. Manufacturers with products approaching or entering negotiation should expect CMS scrutiny of Part D formulary positioning and utilization controls, which reshapes what an effective submission must achieve.

CMS's April 16, 2025 guidance tells Part D sponsors how the agency will evaluate CY 2026 formularies for covered drugs chosen for negotiation under the IRA program. CMS will look for warning signs in submissions, including a selected drug being left off entirely, being assigned worse tiering or cost sharing compared with other brand drugs in the same therapeutic class, step therapy that makes patients try an alternative first, and utilization management rules that treat the selected drug more strictly than competing drugs.

If a formulary is flagged by CMS, the Part D plan may resubmit it or provide supporting rationale as part of the yearly bid evaluation. Such rationale must address clinical factors, including how chosen and excluded medications compare in efficacy, plus adherence to all legal and regulatory requirements. These consequences extend far beyond the medications selected for negotiation. The structure of Part D formularies affects covered entities, health plans, PBMs, and patients, prompting insurers to adjust coverage approaches when rebate leverage on negotiated medications falls below what remains available for other products.

Cell and gene therapies are in an especially uncertain place as this shift plays out. As commercial plans drop more indications from coverage, IRA negotiation schedules and unsettled pricing rules make confident reimbursement planning for these therapies more difficult. This unresolved divide still warrants close attention.

For manufacturers of drugs at risk of IRA selection, the practical implication is direct: dossiers and formulary justification materials both need to speak clearly to clinical superiority, non-inferiority, or equivalence arguments. CMS now reads those arguments too, alongside the P&T committee. The dossier has picked up a second audience, and that audience carries regulatory weight the P&T committee never did.

What a strong dossier submission looks like in practice

To satisfy P&T expectations, a dossier has to go beyond addressing the Format’s required sections. It starts with the questions reviewers are most likely to press, puts the key numbers within quick reach, and is clear about what its evidence can and cannot show. The same benchmark also helps confirm that nothing required by Version 5.0 has been missed.

Section 1 calls for up-to-date prescribing information, how the drug works, dosing details, which tier is proposed, and any applicable REMS details; Section 2 calls for pivotal trial evidence broken down by subgroups, network meta-analyses or indirect comparisons when no head-to-head data exist, and RWE reflecting how representative the population is for the specific plan; Section 3 calls for a budget impact model adaptable to the plan's own population and an analysis of cost-effectiveness built on openly stated assumptions, clear time horizons, plus sensitivity analyses; and Section 4 calls for validated PRO instruments with minimally important differences reported, paired with a clear value summary. DTx products carry extra requirements around software compatibility, how systems connect, HIPAA obligations, and user-interaction data, as well as device usability. All submissions now gain from covering health-disparities evidence and fair medication pricing under the guidance in Version 5.0.

Drugmakers tend to trip up in three familiar areas. Payers gripe most about overly lengthy disease background sections, prompting Version 5.0 to shrink page allowances as a direct fix. RWE arrives without confirming that trial participants reflect the plan's enrolled population, which triggers the familiar generalizability pushback reviewers instinctively deliver. Financial projections show up tailored to an average cohort rather than letting a plan's team adapt them to real enrollment and spending patterns, undermining the whole point of budget impact modeling. Fixing these three problems does not call for a bigger dossier. Instead, dossiers must be more precise, shaped by practical reviewer needs rather than a desire to fill every available space.